Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 15/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | GLA | P06280 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | NPY1R | P25929 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | SUMO3 | P55854 | 1/20 | 0.58 |
| ▸ | SUMO2 | P61956 | 1/20 | 0.58 |
| ▸ | SUMO1 | P63165 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9287754 | 0.84 | SUMO3 (0.72) | APPMEN1KMT2AKDM4EGLA | |
| SCHEMBL4980653 | 0.81 | KMT2A (0.59) | MEN1KMT2AKDM4EGLATSHR | |
| SCHEMBL4864986 | 0.80 | PDE5A (0.64) | MEN1KMT2AKDM4EGLATSHR | |
| SCHEMBL13009791 | 0.78 | APP (1.00) | APPMEN1KMT2AKDM4EMAPT | |
| SCHEMBL10838568 | 0.78 | APP (0.74) | APP | |
| SCHEMBL5238637 | 0.77 | KMT2A (0.54) | MEN1KMT2AKDM4EGLATSHR | |
| SCHEMBL4864291 | 0.76 | KDM4E (0.53) | APPMEN1KMT2AKDM4EGLA | |
| SCHEMBL18072302 | 0.75 | APP (0.66) | APP | |
| SCHEMBL560210 | 0.75 | POLB (0.58) | MEN1KMT2AKDM4EGLATSHR | |
| SCHEMBL7683602 | 0.74 | CCNA2 (0.43) | MEN1KMT2AMAPTRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569925-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2005-09-07 | — | — | EP | claimed |
| WO-2004055003-A1 | 2-SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS CAPSAICIN RECEPTOR MODULATORS | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | claimed |
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | NEUROGEN CORPORATION (US) | 2008-01-17 | — | — | US | disclosed |
| US-7304059-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1720542-A4 | ARYLALKYLAMINO-SUBSTITUTED QUINAZOLINE ANALOGUES | NEUROGEN CORP (US) | 2007-11-28 | — | — | EP | disclosed |
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | NEUROGEN CORPORATION (US) | 2007-09-20 | — | — | US | disclosed |
| CN-1950081-A | Arylalkylamino-substituted quinazoline analogues | NEUROGEN CORP (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1720542-A1 | ARYLALKYLAMINO-SUBSTITUTED QUINAZOLINE ANALOGUES | NEUROGEN CORPORATION (US) | 2006-11-15 | — | — | EP | disclosed |
| US-20060173003-A1 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-08-03 | — | — | US | disclosed |
| US-7074799-B2 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION (US) | 2006-07-11 | — | — | US | disclosed |
| EP-1581225-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2005-10-05 | — | — | EP | disclosed |
| WO-2005087227-A1 | ARYLALKYLAMINO-SUBSTITUTED QUINAZOLINE ANALOGUES | NEUROGEN CORPORATION (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1471910-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN RECEPTORS | NEUROGEN CORPORATION (US) | 2004-11-03 | — | — | EP | disclosed |
| US-20040156869-A1 | 2-substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION | 2004-08-12 | — | — | US | disclosed |
| US-20040142958-A1 | Combination therapy for the treatment of pain | NEUROGEN CORPORATION | 2004-07-22 | — | — | US | disclosed |
| WO-2004054582-A1 | COMBINATION THERAPY FOR THE TREATMENT OF PAIN | NEUROGEN CORPORATION (US) | 2004-07-01 | — | — | WO | disclosed |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | NEUROGEN CORPORATION | 2004-06-03 | — | — | US | disclosed |
| WO-2003062209-A2 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES AS MODULATORS OF CAPSAICIN | NEUROGEN CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015183-A1 | SUBSTITUTED QUINAZOLIN-4-YLAMINE ANALOGUES | PIGS, HRH4, GPR88 | APP 4613/4885MEN1 3817/4885KMT2A 2200/4885 |
| US-20040142958-A1 | Combination therapy for the treatment of pain | OPRK1, OPRL1, OPRM1 | APP 4399/4885MEN1 4577/4885KMT2A 2232/4885 |
| US-20070219203-A1 | Arylalkylamino-substituted quinazoline analogues | PIGS, GPR35, HRH4 | APP 4450/4885MEN1 4625/4885KMT2A 3387/4885 |
| US-20040156869-A1 | 2-substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | APP 4383/4885MEN1 3835/4885KMT2A 2098/4885 |
| US-20060173003-A1 | Substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | APP 4613/4885MEN1 3817/4885KMT2A 2200/4885 |
| US-20040106616-A1 | Substituted quinazolin-4-ylamine analogues | PIGS, HRH4, GPR88 | APP 4607/4885MEN1 3714/4885KMT2A 2473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.